These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26835903)

  • 1. Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease.
    Mostamand S; Schroeder S; Schenkein J; Miloh T
    J Pediatr Gastroenterol Nutr; 2016 Jul; 63(1):94-7. PubMed ID: 26835903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
    J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study.
    Gibson M; Subedi S; Barker DH; Masur S; Mallette MM; Lingannan A; Recinos Soto AA; Esharif D; Maxwell SH; Riaz MS; Herzlinger MI; Shalon LB; Cerezo CS; Kasper VL; Ross AM; Leleiko NS; Shapiro JM
    J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):207-213. PubMed ID: 37084343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
    Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
    Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury from initial dose of infliximab.
    Cheng FK; Bridges EE; Betteridge JD
    Mil Med; 2015 Jun; 180(6):e723-4. PubMed ID: 26032391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
    Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
    Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNFα Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease.
    Nedelkopoulou N; Vadamalayan B; Vergani D; Mieli-Vergani G
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):100-105. PubMed ID: 28953529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Choe YH
    Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
    Cardile S; Candusso M; Papadatou B; Bracci F; Knafelz D; Torre G
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):736. PubMed ID: 28441268
    [No Abstract]   [Full Text] [Related]  

  • 17. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
    J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis.
    Gemmell A; Fraser A; Oien K; Seenan JP
    BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37879703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.